Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 6/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | YARS1 | P54577 | 2/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | NPY4R | P50391 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10715137 | 1.00 | MME (0.58) | MMESLC7A5ACECPA1ACE2 | |
| SCHEMBL30122989 | 0.96 | MME (0.54) | MMESLC7A5ACECPA1ACE2 | |
| SCHEMBL29630361 | 0.96 | MME (0.54) | MMESLC7A5ACECPA1ACE2 | |
| SCHEMBL30839491 | 0.95 | MME (0.53) | MMESLC7A5ACECPA1ACE2 | |
| SCHEMBL30123104 | 0.93 | ENPEP (0.56) | MMESLC7A5ACECPA1ACE2 | |
| SCHEMBL29619568 | 0.93 | ENPEP (0.56) | MMESLC7A5ACECPA1ACE2 | |
| SCHEMBL29430160 | 0.92 | ENPEP (0.55) | MMESLC7A5ACECPA1ACE2 | |
| SCHEMBL1574161 | 0.91 | SLC7A5 (0.65) | MMESLC7A5ACECPA1ACE2 | |
| SCHEMBL1574158 | 0.91 | SLC7A5 (0.65) | MMESLC7A5ACECPA1ACE2 | |
| SCHEMBL31025673 | 0.91 | SLC7A5 (0.65) | MMESLC7A5ACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| CN-120195298-A | Metabolic marker composition for discriminating tobacco grades, screening method and application | 哈尔滨脉图精准技术有限公司 | 2025-06-24 | — | — | CN | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| CN-117586347-A | A hirudin with antidiabetic activity and its application | 滨州医学院 | 2024-02-23 | — | — | CN | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| US-11382911-B2 | Plant extract containing diketopiperazine and method for producing same | SUNTORY HOLDINGS LIMITED (JP) | 2022-07-12 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| WO-2020071258-A1 | PROTEIN GLYCATION SUPPRESSANT | 味の素株式会社 | 2020-04-09 | — | — | WO | claimed |
| US-20020147317-A1 | Fluorogenic compounds and uses therefor | 3M INNOVATIVE PROPETIES COMPANY | 2002-10-10 | — | — | US | claimed |
| US-6372895-B1 | USEFUL IN ASSAYING FOR BIOLOGICAL ACTIVITY | 3M INNOVATIVE PROPERTIES COMPANY | 2002-04-16 | — | — | US | claimed |
| EP-0122151-B1 | PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | claimed |
| US-4783402-A | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1988-11-08 | — | — | US | claimed |
| EP-0122151-A2 | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1984-10-17 | — | — | EP | claimed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-4242256-A | Synthesis of peptide analogues | SHARPE ROBERT (GB) | 1980-12-30 | — | — | US | disclosed |
| US-3963691-A | POLYPEPTIDES, PEPTIZATION | MERCK & CO., INC. (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147317-A1 | Fluorogenic compounds and uses therefor | NOTUM, WEE1, CPSF7 | MME 815/4885SLC7A5 2103/4885ACE 2808/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | MME 2240/4885SLC7A5 2919/4885ACE 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.